newest prostate cancer treatments | A Promising New Therapy for Advanc

Keyword	CPC	PCC	Volume	Score	Length of keyword
newest prostate cancer treatments	0.74	0.4	6013	83	33
newest	1.6	0.2	8733	75	6
prostate	0.16	0.8	6328	98	8
cancer	1.96	0.7	2338	46	6
treatments	1.8	0.6	7119	84	10

Keyword	CPC	PCC	Volume	Score
newest prostate cancer treatments	0.66	0.6	7610	50

Search Results related to newest prostate cancer treatments on Search Engine

A Promising New Therapy for Advanced Prostate Cancer
mskcc.org

https://www.mskcc.org/news/new-therapy-promises-major-advance-treating-prostate

WebJun 3, 2021 · Prostate cancer treatment stands on the brink of a major advance with the development of a new treatment that zeros in on cancer cells to destroy them. The therapy, called 177 Lu-PSMA-617, uses a molecule that selectively seeks out and attaches to a specific protein on the cancer cell surface.

DA: 84 PA: 34 MOZ Rank: 4

FDA approves new treatment for advanced prostate cancer
harvard.edu

https://www.health.harvard.edu/blog/fda-approves-new-treatment-for-advanced-prostate-cancer-202307122952

WebJul 12, 2023 · In June, the FDA approved a new treatment for the most advanced type of prostate cancer. Patients who have this condition, which is called metastatic castration-resistant prostate cancer (mCRPC), have few therapeutic options, so the approval helps to fill an urgent need.

DA: 82 PA: 50 MOZ Rank: 4

FDA Approves First Oral Hormone Therapy for Treating Advanced Prostate
fda.gov

https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-hormone-therapy-treating-advanced-prostate-cancer

WebDec 18, 2020 · FDA News Release. FDA Approves First Oral Hormone Therapy for Treating Advanced Prostate Cancer. For Immediate Release: December 18, 2020. Today, the U.S. Food and Drug Administration approved...

DA: 96 PA: 21 MOZ Rank: 53

FDA Approves Promising Therapy for Advanced Prostate Cancer: …
mskcc.org

https://www.mskcc.org/news/fda-approves-promising-therapy-advanced-prostate

WebMar 23, 2022 · Prostate cancer treatment took a major step forward today as the U.S. Food and Drug Administration approved a new therapy that zeros in on cancer cells to destroy them. The treatment, called 177 Lu-PSMA-617, uses a molecule that selectively seeks out and attaches to a specific protein on the cancer cell surface called PSMA …

DA: 94 PA: 37 MOZ Rank: 33

Talazoparib Combo Approved for Metastatic Prostate Cancer
cancer.gov

https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-talazoparib-enzalutamide-prostate-cancer

WebAug 4, 2023 · The Food and Drug Administration (FDA) has approved the combination of enzalutamide (Xtandi) with talazoparib (Talzenna) as an initial treatment for some people with metastatic castration-resistant prostate cancer.

DA: 54 PA: 20 MOZ Rank: 60

A new treatment for advanced prostate cancer improves survival …
harvard.edu

https://www.health.harvard.edu/blog/a-new-treatment-for-advanced-prostate-cancer-improves-survival-in-phase-3-clinical-trial-202107122543

WebJul 12, 2021 · One of these new therapies is now generating promising data for men with the most aggressive prostate cancer. Radiation therapy is getting more precise, making it easier to kill tumors while sparing their surrounding tissues.

DA: 82 PA: 36 MOZ Rank: 70

FDA Approves Relugolix for Advanced Prostate Cancer - NCI
cancer.gov

https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-relugolix-prostate-cancer-androgen-deprivation-therapy

WebJan 26, 2021 · A new drug approved by the Food and Drug Administration (FDA) is expected to immediately affect the treatment of some men with prostate cancer. In a large clinical trial, the drug, relugolix (Orgovyx), was shown to be more effective at reducing testosterone levels in men with advanced prostate cancer than another commonly used treatment ...

DA: 45 PA: 5 MOZ Rank: 6

FDA approves Pluvicto for metastatic castration-resistant prostate cancer
fda.gov

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer

WebOn March 23, 2022, the Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the treatment of...

DA: 20 PA: 31 MOZ Rank: 31

New treatment approved for late-stage prostate cancer
harvard.edu

https://www.health.harvard.edu/blog/new-treatment-approved-for-late-stage-prostate-cancer-202204072722

WebApril 7, 2022. By Charlie Schmidt, Editor, Harvard Medical School Annual Report on Prostate Diseases. In late March, the FDA approved a new therapy for advanced prostate cancer that is metastasizing, or spreading, in the body.

DA: 15 PA: 9 MOZ Rank: 37

FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer
cancer.gov

https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-olaparib-rucaparib-prostate-cancer

WebJun 11, 2020 · TRITON3 was a follow-up trial to TRITON2, the results of which formed the basis for FDA’s 2020 approval of rucaparib for people with metastatic, castration-resistant prostate cancer with BRCA mutations. The TRITON2 results and details of the initial FDA approval are described in the story below.

DA: 48 PA: 100 MOZ Rank: 37